BUY Glenmark Pharmaceuticals — Jefferies India, 04 Aug 2026

BUYGlenmark Pharmaceuticals

Glenmark Pharmaceuticals share price target & all analyst calls

byJefferies IndiaHorizon: NA (inferred 1 year)4 Aug 2026via NDTV Profit

Entry₹2,238Inferred

Target₹2,590

Total upside +15.73%

Stop lossNot given

CMP₹2,3318h ago

Active+4.16%+11.11%upside left 10 mo left

Follow Jefferies India for new calls(97% target hit, 39 closed calls)Get alerts Watch GLENMARK for new buy/sell callsGet alerts See 4 other Long-term calls on GLENMARK See 148 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 2 Oct, 12:37 am IST

33 supporting11 neutral2 opposing

Supports the BUY call (33)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·1 Oct · today

Glenmark Pharma FY26 PAT Rises 30.1% to ₹13,620 Million; Q4 EBITDA Jumps to ₹9.4b

NewsGoogle News·27 Sept · 4d ago

Glenmark Pharma gets EIR for Goa facility from US FDA

NewsGoogle News·23 Sept · 1w ago

Glenmark Receives US FDA Inspection Report For Goa Facility; Shares Rise 0.28%

NewsGoogle News·23 Sept · 1w ago

Glenmark Pharmaceuticals trades higher on getting EIR with VAI status for Goa facility

NewsGoogle News·23 Sept · 1w ago

Neutral / worth noting (11)

Glenmark Pharmaceuticals (NSE: GLENMARK) U.S. FDA Compliance Update for Goa Facility

NewsGoogle News·23 Sept · 1w ago

Glenmark transfers nebulizer brands to subsidiary for ₹223 Cr

NewsGoogle News·23 Sept · 1w ago

Weighs against the BUY call (2)

1 other SEBI-registered advisor has an active long-term SELL call on this stock

Advisor consensus · same horizon·3 Feb · 8mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.